BREAST-Q是评价保乳治疗（BCT）患者满意度和生活质量的重要工具，但由于缺乏得分解释指导而限制了其临床实用性。本研究确定了BREAST-Q BCT模块的参考值和最小重要差异（MID）。回顾性研究了2011年1月至2021年12月间Memorial Sloan Kettering癌症中心的BCT患者。描述性统计法用于总结BREAST-Q中位数得分。基于基线BREAST-Q得分的0.2个标准差和基线和手术后1年差异的0.2个标准化响应平均值，分布分析估计了MID。还估计了基于体重指数、放射线和再切割的不同临床分组的MID。总计有8060名患者用于确定参考值，5673名患者用于估计MID。所有培训中介估计值范围为3到5分；确定4分适用于临床实践和研究。除胸部身体健康外，所有领域的中位数BREAST-Q分数在手术后2年时呈上升趋势并稳定。根据25个百分位数、中位数和75个百分位数轨迹，创建了一个得分解释工具——实时参与和沟通工具。参考值和MID对BREAST-Q得分解释至关重要，这可以带来改善临床评估和决策以及改善研究方法学的作用。未来的研究应在不同的患者队列中验证本研究的结果。©2023。外科肿瘤学会。

The BREAST-Q is an important tool for evaluating patient satisfaction and quality of life in breast-conserving therapy (BCT) patients, but its clinical utility is limited by the lack of guidance on score interpretation. This study determines reference values and the minimal important difference (MID) for the BREAST-Q BCT module.A retrospective review of BCT patients at Memorial Sloan Kettering Cancer Center from January 2011 to December 2021 was performed. Descriptive statistics were used to summarize median BREAST-Q scores. Distribution-based analyses estimated MIDs based on 0.2 standard deviation of baseline BREAST-Q scores and 0.2 standardized response mean of the difference between baseline and 1-year postoperative BREAST-Q scores. MIDs for different clinical groupings based on body mass index, radiation, and reexcision also were estimated.Overall, 8060 patients were included for determining reference values, and 5673 patients were included for estimating MIDs. Median BREAST-Q scores trended upwards and stabilized by 2 years after surgery for all domains except Physical Well-Being of the Chest, which decreased and stabilized by 2 years. A score interpretation tool, the Real-Time Engagement and Communication Tool, was created based on 25th percentile, median, and 75th percentile scores trajectories. All MID estimates ranged from 3 to 5 points; 4 points was determined to be appropriate for use in clinical practice and research.Reference values and MIDs are crucial to BREAST-Q score interpretation, which can lead to improved clinical evaluation and decision making and improved research methodology. Future research should validate this study's findings in different patient cohorts.© 2023. Society of Surgical Oncology.